ARX (ASX) Come on finish 1.60 plus

Originally posted by Mattycarcar: ↑

hey thomb

Me too. I researched the three stock.
I found ARX and PNV the most promising.
AvH was loosing too much money a year currently and a lot more cash raises coming for that one.
You'd think ARX was better value; if you looked at it's 82 vs 47% growth, more products for sale, the Ovitex with Tela Bio kicking goals in the US, they have guidance this next FY PNV didn't, lots of staff in US to support expansion and more cash in the bank.

But I went with PNV; here is why;

integra is the gold standard of care in the US and arguably globally. It's a biologic. Porcine. ARX is also biologic. It's sheep. ARX claim to be significantly cheaper, but I've not seen any independent journals suggesting how much by or even if it is. It's growth in sales would suggest so.
I didn't like the cash burn of ARX. PNV even though less cash in bank is much more profitable and only loosing 1 million this year. The big thing is margin. PnV is 96% margin and improving. ARX was 70% now 76% and improving with its new products. However this is where things get interesting. PNV is by far the cheapest option and it's performs beats Intwgra on every front. Less infections lower cost and aesethically better appearance. On margins if PNV halve it's prices it can still be making 90% margin; but the impact this would have on ARX and Integra which are already more expensive to make (lower margin) and higher priced would result Ina drastic reduction in margin to these companies. Thinking along the lines of margin falling from 76 to 30% quite easily. So PNV is the clear dominant winner due to its much lower cost of production.

Pnv is the only synthetic on the market (so it has no synthetic competition. Very easy for a sales person to sell that story. Whereas ARX need to sell the story of choosing one biologic over another. And that's tough. Pigs are being tested now where they are being modified at embryo with human phenotype to have a pig that's got a mixture of pig and human DNA; for organ transplant these organs are then accepted more so like O blood types. So I can't see use of pigs going away for medical applications.

Leadership; ARX are kicking goals;but the strength of PNV new CEO and their new Scientific Officer blitz ARX all day long. Strategically PNV have a better leadership team to strategically grow PNV.

I think both companies have a strong future. But if someone like Barda need to make a choice as to which product to stockpile for US emergency a a synthetic has a much longer shelf life over any biologic.

PnVs but weakness IMHO at the moment is they cannot get their distributors firing. Growth of sales in them is dismal. But that could turn around drastically if they start changing distributors which is very easily done.
i forecast both companies to grow 50-60% this year which in healthcare is high growth.
its a buy for both for me, but I hold PNV for now. Better more experienced glob management and the only synthetic on market will trump in the long term imho.
Pnv has about 5-10 times more independent journal articles too. Lots of doctors are writing on it. Not so much with Aroa yet.
Not a good look when the white volcano disaster in NZ, and Emergency depts there/ surgeons chose Polynovo, an Aussie company over Aroa, a NZ company. What's that tell you?

Expand

u are terribly wrong about cash burn:
PNV lost $1.5m cash and only has $6m left. even its small reduction in cash balance was achieved partially by selling its property for $6.3m. be noted this is a sale-and-leaseback, which won't reduce its financial liability.

ARX Vs PNV? on balance sheet position? u gonna be kidding me lol. Shorters are like flies: they like cash bleeding companies with weak balance sheet.

let's move on pls. it's like comparing apple to orange

No.	Vol.	Price($)
1	15159	47.5¢

No.

Vol.

Price($)

15159

47.5¢

Price($)	Vol.	No.
49.0¢	16383	4

Price($)

Vol.

No.

49.0¢

16383

No.	Vol.	Price($)
1	15159	0.475
1	4600	0.465
2	24388	0.455
3	8233	0.450
3	35112	0.445

No.

Vol.

Price($)

15159

0.475

4600

0.465

24388

0.455

8233

0.450

35112

0.445

Price($)	Vol.	No.
0.480	2388	1
0.490	22178	3
0.495	31898	2
0.500	4326	2
0.505	12600	1

Price($)

Vol.

No.

0.480

2388

0.490

22178

0.495

31898

0.500

4326

0.505

12600

(20min delay)
Last 48.0¢		Change 0.025(5.49%)		Mkt cap ! $163.4M

Open	High	Low	Value	Volume
47.0¢	48.0¢	47.0¢	$15.14K	31.90K

u are terribly wrong about cash burn:PNV lost $1.5m cash and...

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

The Rising Tide: How institutional adoption is shaping the future of crypto

After $15M MinRes plant sale fell through, Poseidon Nickel flags gold rock chips at Lake Johnston

Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

u are terribly wrong about cash burn:PNV lost $1.5m cash and...

Top Stories

How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

The Rising Tide: How institutional adoption is shaping the future of crypto

After $15M MinRes plant sale fell through, Poseidon Nickel flags gold rock chips at Lake Johnston

Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News